Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: maileg who wrote (324)	4/17/1998 12:28:00 PM
From: Apache Indian	Respond to of 1494

Actually my experience with OTCBB has been almost opposite. ITs highly volatile on even low volumne. With a story and volume like this, this stock should have crossed 2+ today and found a new trading range!! Also, the volume over the last two months has been so low, along with the small float for this stock, I cant imagine the Market Makers have so much inventory... If they were all buys today then the stock would have skyrocketed, maybe they are just happy making the 10% spread, and some people are actually unloading because of the loss of the patents.. This is the first time I've been in a stock before the news breaks, (all the other times I came inafter the news and mostly lost money) and this time I was looking for a ride the day the merger news comes out, I think its just me, DoH! (like Homer would say)

To: maileg who wrote (324)	4/17/1998 12:48:00 PM
From: John Dwyer	Read Replies (1) \| Respond to of 1494

Hi Darci, Well, I'm a bit disappointed myself. If you look at the details of the deal though, it is unclear how good this is. While it appears that they will receive important synergies with Merz on the Memantine front, they only received about $2 million in upfront payments. Therefore, unless Merz pays for the entire cost of the Phase III trial NTII can't start it without another deal. It appears that they have played their trump card and have managed to buy some time. I think it's interesting that Merz has Phase III trials in Europe for other indications, and it appears that NTII might share in the revenues from these indications... I don't understand that part, I'm probably mistaken. However, this does not seem to be a ringing endorsement for NTII. Still, from a position of extreme weakness, I think NTII did pretty well. It is still not clear whether NTII will be around six months from now and I think that is probably why the response today has been somewhat muted. John